根据协议条款，博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用。博奥信还将获得Aclaris Therapeutics ...

▲点击上方的蓝色“医谷”关注我们日前，博奥信生物宣布与Aclaris ...

周二，Aclaris Therapeutics (NASDAQ: ACRS)宣布与Biosion达成重要的许可协议，获得两种潜在炎症治疗药物的全球权利（不包括中国）。这些许可的化合物包括BSI-045B（也称为TQC2731，一种抗TSLP单克隆抗体）和BSI-502（一种抗TSLP加抗IL4R双特异性抗体），两者都旨在治疗特应性皮炎和其他炎症性疾病。 公告详细介绍了Aclaris分享的BSI-0 ...

- 博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用，同时博奥信还将获得 Aclaris Therapeutics 19.9% ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

2024年11月18日，博奥信宣布将TSLP抗体BSI-045B、TSLP/IL-4R双抗的大中华区外全球权益授权给Aclaris ...

周二，BTIG将Aclaris Therapeutics Inc. (NASDAQ:ACRS)的股票评级从中性上调至买入。该公司还为Aclaris设定了8.00美元的新目标价，表明对该公司股票前景持积极态度。

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...